CD4 and myeloid sarcoma: On the other hand, various human studies have reported impaired immune activities of CD4+CD25+ Tregs derived from MS patients, rather than decreased Tregs numbers25–28, thereby providing another advantage of using antigen-specific Tregs for MS treatment.